Completed PHASE2 INTERVENTIONAL 4-arm NCT02361424

Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD) (PLEODIAL-I)

First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients

Sponsor: Ascopharm Groupe Novasco

Conditions Alzheimer Disease

Interventions PXT00864 placebo

Updated 6 times since 2017 Last updated: Feb 12, 2016 Started: Feb 28, 2013 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Ascopharm Groupe Novasco and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ascopharm Groupe Novasco
Pharnext S.C.A.

Data source: Pharnext S.C.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bordeaux, France